Accuray (ARAY) Q4 2021 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2021 earnings summary
9 Nov, 2026Executive summary
FY21 revenue rose 3% YoY to $396.3m; operating income increased to $22.2m from $12.5m, while net results shifted to a $6.3m loss from $3.8m income.
COVID-related delivery and installation delays continued to slow backlog conversion; delays were expected to persist into FY22.
Financial highlights
Product revenue increased 6% to $176.6m; service revenue increased 2% to $219.6m.
Gross profit rose 7% to $159.5m; service gross profit increased 9% to $85.0m and product gross profit increased 4% to $74.5m.
Other expense, net, increased to $27.7m, including $9.9m of debt-extinguishment losses; FY20 included a $13.0m non-cash gain on the China JV contribution.
Net loss was $6.3m, or $0.07 per diluted share, versus net income of $3.8m, or $0.04 per diluted share, in FY20.
Outlook and guidance
Delivery and installation delays were expected to continue into FY22 and negatively affect revenue; the duration and financial impact of COVID-19 remained uncertain.
Management expected cash, available debt facilities, and anticipated cash flows to fund operations for at least 12 months.
Remaining system performance obligations were $1,009.4m; 20%–27% was estimated for recognition in the next 12 months, while historical experience indicated ~26% may be cancelled.
Revenue from remaining awarded China Class A licenses was anticipated over the next 12–18 months.
Latest events from Accuray
- FY13 system-sales weakness and MLC delays drove losses despite service growth.ARAY
Q4 2013 - Revenue and orders rebounded; adjusted EBITDA turned positive, but execution risks remained.ARAY
Q4 2014 - Record Q4 orders and constant-currency gains were offset by FX pressure and execution risks.ARAY
Q4 2015 - Record backlog and $24.6M adjusted EBITDA marked progress despite a $25.5M net loss.ARAY
Q4 2016 - Revenue and margin improved in FY18, but net orders weakened as cancellations and age-outs rose.ARAY
Q4 2018 - Record backlog and Radixact demand met lower revenue, weaker margins and continued losses.ARAY
Q4 2017 - TomoTherapy-led growth lifted revenue, but losses, cash use and conversion risks persisted.ARAY
Q4 2019 - Profitability returned, but COVID-19 delayed deliveries and backlog conversion.ARAY
Q4 2020 - Revenue grew, but margin compression and persistent cost pressures deepened the loss.ARAY
Q4 2023